ReviewCancer journal (Sudbury, Mass.)
Studying a complex tumor: potential and pitfalls.
Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Multi-Transcriptomic Analysis Reveals GSC-Driven MES-Like Differentiation via EMT in GBM Cell-Cell Communication.Biomedicines · 2025Article
- Intratumoral Cell Heterogeneity in Patient-Derived Glioblastoma Cell Lines Revealed by Single-Cell RNA-Sequencing.International journal of molecular sciences · 2024Article
- Biological Implications and Functional Significance of Transglutaminase Type 2 in Nervous System Tumors.Cells · 2024Review
- Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma.Cells · 2022Review
- Multi-Omics Analysis of Glioblastoma and Glioblastoma Cell Line: Molecular Insights Into the Functional Role of GPR56 and TG2 in Mesenchymal Transition.Frontiers in oncology · 2022Article
- Advances in Research of Adult Gliomas.International journal of molecular sciences · 2021Review
- The landscape of the mesenchymal signature in brain tumours.Brain : a journal of neurology · 2019Article
- Exosomes derived from microRNA-584 transfected mesenchymal stem cells: novel alternative therapeutic vehicles for cancer therapy.BMB reports · 2018Article
- Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.Cell death & disease · 2017Article
- Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.Cancer cell · 2017Article
- GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity.Neuro-oncology · 2014Review
- Recurrent glioblastoma multiforme versus radiation injury: a multiparametric 3-T MR approach.La Radiologia medica · 2014Article
- Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge.Nature reviews. Cancer · 2014Review
- Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment.Frontiers in oncology · 2014Review
- Using the molecular classification of glioblastoma to inform personalized treatment.The Journal of pathology · 2014Review
- Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth.Cancer letters · 2013Article
- A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival.Genes & development · 2013Article
- Biomarkers classification and therapeutic decision-making for malignant gliomas.Current treatment options in oncology · 2012Article
- The cellular origin for malignant glioma and prospects for clinical advancements.Expert review of molecular diagnostics · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Glioblastoma multiforme is a histopathologically heterogeneous disease with few treatment options. Therapy based on genomic alterations is rapidly gaining popularity because of the high response rate and high specificity. DNA copy number and exon-sequencing studies of glioblastoma multiforme samples have revealed recurrent genomic alterations in genes such as TP53, EGFR, and IDH1, but to date, this has not resulted in novel glioblastoma multiforme therapies. Identification of expression subtypes has resulted in new insights such as the association between genomic abnormalities and expression signatures. This review describes the types of genomic studies that have been performed and that are underway, the most prominent results, and the implications of genomic research for the development of clinical treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.